



20<sup>th</sup> October 2020

### **ASX Announcement**

#### **QUARTERLY ACTIVITIES, CASHFLOW REPORT and OPERATIONS UPDATE**

*Quarter ended 30<sup>th</sup> September 2020*

Lifespot Health Ltd (ASX:LSH) ("Lifespot or the Company") is pleased to provide the quarterly activities and cash flow report and update of operations.

Operational highlights are as follows:

- Cash reserves as at 30<sup>th</sup> September 2020 were \$1.129m
- Net cash used in the quarter for operating activities (\$297k)
- Cash receipts for the quarter \$13k
- Successful capital raising of \$960k by private placement

Net cash used during the quarter was \$297k, reflecting a lean Australian operational model with investments focused on business development activities. All German operational costs have ceased with an insubstantial amount being paid to retain consulting services and finalising winddown costs.

Sales of the Fevertel system for households and small business totalled \$12k. Initial sales have primarily been to organisations involved in trialling and running return to workplace management. Pharmacy distributor sales have been weak and excessively margin dilutive due to restrictions in acceptance of new products in major pharmacy chains during COVID business restrictions and the very aggressive on-line and instore pricing of competitor products.

The Company issued 24,000,000 ordinary shares A\$0.04 (4 cents) per share to Cannvalate Pty Ltd raising \$960,000. Cash reserves at the end of the quarter was \$1.129m. Funds raised will be primarily used to fund clinical trials and the Company's Bodytel Systems including the Medihale® inhaler device and other novel cannabinoid inhalational devices.

Following the relocation of Bodytel and Seng Vital assets and operational management from Germany to Australia the Company has progressed discussions with a number of Melbourne based clinical research organisations to scope initial target disease areas and outline study protocols.

On the 12<sup>th</sup> October the Company appointed Mr. Matthew Golden as CEO. Matthew's immediate priorities will be to review the Company's Bodytel System strategies, make recommendations to the Board and clearly define the milestones and timing of the Company's Medihale inhaler device clinical safety and pharmacokinetic trials.

Lifespot Health Limited (ACN 611 845 820)  
Suite 103, Level 1,  
2 Queen St Melbourne 3000.  
Phone: 03 8395 5446.



Rodney Hannington and Frank Cannavo have transitioned from their previous executive roles to resume their Non-Executive Chairman and Non-Executive Director roles respectively.

During the September quarter \$217K was spent on the development, production and marketing of Fevertel.

#### **Payments to Directors**

Cash payments to directors during the quarter totalled \$34K.

The Company will provide further updates in due course.

Authorised by the Board of Directors.

#### **For further information:**

[www.lifespot-health.com](http://www.lifespot-health.com)

Twitter - @LifespotH

For further information:

Mr Justyn Stedwell

Company Secretary

Phone 03 8395 5446

#### **About Lifespot Health Ltd.**

##### **CONNECTING HARDWARE WITH SOFTWARE – DIGITAL TECHNOLOGY FOR BETTER HEALTHCARE**

Our core expertise is in connecting medical diagnostic devices and digital medicine delivery systems via Bluetooth and Smart device APPs to our cloud based ISO13485 accredited Bodytel patient management system. Our systems and applications are cloud and smartphone-based and easy to use.

We provide our diagnostic systems and medicine delivery platforms to healthcare enterprises for own branding white label contracts. Our German based BodyTel™ system is based on modern and future-proof internet technology utilizing advanced technologies such as document-based databases and biological neural networks.

Our German based Seng-Vital is specialized in development of hardware in the medical and non-medical Cannabis categories. In 2019 the company launched Medihale®, a digitally integrated medical cannabis vaporiser hardware and software solution that incorporates Bodytel App's to be the world's first fully integrated vaporising system. The Company continues to lead the way in innovative vaporiser hardware and software for OEM clients.

Lifespot Health Limited (ACN 611 845 820)  
Suite 103, Level 1,  
2 Queen St Melbourne 3000.  
Phone: 03 8395 5446